Baculovirus-Based Vaccines
AssigneesKonkuk University Industrial Cooperation Corp., KR Biotech Co., Ltd.
InventorsYoung-Bong Kim, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
Life of this patent
Estimating the term…
Abstract
The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.
Claims18
A recombinant baculovirus comprising:
- (a) a nucleotide sequence encoding a foreign virus envelope protein derived from a retrovirus;
- (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence;
- (c) a nucleotide sequence encoding an antigen protein;
- and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence.
7-8. (canceled)
15-16. (canceled)
A nucleic acid molecule encoding a HERV (human endogenous retrovirus) envelope protein, comprising the nucleotide sequence of SEQ ID NO:1.
Dependencies are inferred from the claim text.